Osimertinib with chemotherapy in advanced non-small cell lung cancer with vaginal metastasis harboring

Background: In recent years, significant progress has been achieved in the treatment of non-small cell lung cancer (NSCLC). The emergence of gene sequencing technology has revolutionized the management of patients with driver gene mutations, offering substantial survival benefits to patients with actionable oncogenic mutations. Epidermal growth factor receptor ( Case Description: We present a case of 54-year-old non-smoking woman with a history of uterine fibroids (total hysterectomy in 2008) and depression (on mirtazapine). She underwent left upper lobectomy for lung adenocarcinoma (LUAD) (pathological stage: pT2N0M0) in 2020, with no recurrence observed after the lobectomy. In January 2024, she was initially diagnosed with a vaginal tumor due to intermittent vaginal bleeding for four months following intercourse. She received two cycles of neoadjuvant chemotherapy (carboplatin 577 mg + paclitaxel 259 mg), achieving a partial response (PR). In March 2024, she underwent radical surgery and postoperative pathological examination confirmed that the vaginal tumor originated from lung cancer. Next-generation sequencing (NGS) revealed co-mutations in Conclusions: In patients with a history of lung cancer presenting with a vaginal mass, the possibility of vaginal metastasis from lung cancer should be carefully evaluated and advanced diagnostic methods such as NGS are recommended. This case highlights the advantages of comprehensive NGS followed by chemotherapy and osimertinib in managing NSCLC with vaginal metastasis and